We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

101 hedge funds and large institutions have $153M invested in C4 Therapeutics in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more call options, than puts

Call options by funds: $738K | Put options by funds: $152K

132% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 19

50% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 16

31% more capital invested

Capital invested by funds: $117M → $153M (+$35.9M)

8.57% more ownership

Funds ownership: 73.82% → 82.39% (+8.6%)

4% more funds holding

Funds holding: 97 → 101 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
101
Holders Change
+4
Holders Change %
+4.12%
% of All Funds
1.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
24
Increased
44
Reduced
19
Closed
16
Calls
$738K
Puts
$152K
Net Calls
+$586K
Net Calls Change
+$425K

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$22.4M
2
RCM
RA Capital Management
Massachusetts
+$19M
3
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$14.4M
4
Morgan Stanley
Morgan Stanley
New York
+$9.5M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.99M

Top Sellers

1
O
OrbiMed
New York
-$9.07M
2
SCM
Soleus Capital Management
Connecticut
-$7.7M
3
TCM
Tang Capital Management
California
-$2M
4
Millennium Management
Millennium Management
New York
-$1.77M
5
WA
Wasatch Advisors
Utah
-$1.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAP
101
Arax Advisory Partners
Colorado
$36 -$85 -36 -65%
TCM
102
Tang Capital Management
California
– -$2M -900,000 Closed
Jacobs Levy Equity Management
103
Jacobs Levy Equity Management
New Jersey
– -$1.12M -503,145 Closed
SC
104
Shay Capital
New York
– -$932K -420,000 Closed
AG
105
Algert Global
California
– -$236K -106,300 Closed
SOW
106
State of Wyoming
Wyoming
– -$183K -82,509 Closed
VCM
107
Voleon Capital Management
California
– -$63.1K -28,420 Closed
Commonwealth Equity Services
108
Commonwealth Equity Services
Massachusetts
– -$46K -20,510 Closed
CIAM
109
Caitong International Asset Management
Hong Kong
– -$42.5K -19,146 Closed
CAPTRUST Financial Advisors
110
CAPTRUST Financial Advisors
North Carolina
– -$33.1K -14,889 Closed
ZIM
111
Zacks Investment Management
Illinois
– -$29K -13,043 Closed
BRWA
112
B. Riley Wealth Advisors
Florida
– -$24.4K -11,000 Closed
JWA
113
JFS Wealth Advisors
Pennsylvania
– -$2.22K -1,000 Closed
WANY
114
Wealthspire Advisors (New York)
New York
– -$222 -100 Closed
ASN
115
Advisory Services Network
Georgia
– -$164 -74 Closed
IA
116
IFP Advisors
Florida
– -$38 -17 Closed
1 2 3 4
5

CCCC Hedge Fund Activity: Q4 2025 in Review

101 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2025, worth a combined $153M — up 31% from $117M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CCCC positions and 16 closed out — a net gain of 8 holders — while 44 added to existing stakes and 19 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $22.4M. The largest seller was OrbiMed, cutting an estimated $9.07M.

  • 101 institutional investors held C4 Therapeutics (CCCC) as of Q4 2025, up from 97 in Q3 2025.
  • Funds reported $153M of C4 Therapeutics stock for Q4 2025, up 31% quarter-over-quarter.
  • 24 funds opened new C4 Therapeutics positions in Q4 2025 and 16 closed out, a net change of +8 holders.
  • The largest C4 Therapeutics buyer in Q4 2025 was Point72 Asset Management, an estimated $22.4M added.
  • The largest C4 Therapeutics seller in Q4 2025 was OrbiMed, an estimated $9.07M sold.

Based on aggregated 13F filings for Q4 2025.